scholarly journals Therapeutic Effect of Epidermal Growth Factor Combined With Nano Silver Dressing on Diabetic Foot Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Kaihua Zhang ◽  
Yiran Li ◽  
Jiarui He ◽  
Jiasheng Xu ◽  
Yanhua Wan ◽  
...  
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Factor Group ◽  
Saline Control ◽  
Control Group ◽  
Nano Silver ◽  
Significant Difference ◽  
Epidermal Growth

Objective: To investigate the clinical efficacy of epidermal growth factor combined with nano silver dressing in the treatment of diabetic foot wounds.Methods: A total of 160 patients with diabetic foot ulcers admitted to the Second Affiliated Hospital of Nanchang University from 2015-06 to 2018-06 were selected to participate in the experiment. A randomized table method was used to randomly divide 160 patients into 4 groups: 40 in the epidermal growth factor group, 40 in the nano-silver dressing group, 40 in the combined group, and 40 in the saline control group (normal saline). The healing stage of the wound surface and the growth degree of granulation tissue were graded. Each group was given a dressing change every other day, and the time required for wound repairing to each healing stage was observed. After 2 and 4 weeks of treatment, the wound exudate was collected for bacterial culture.Results: There was no significant difference in the time between the four groups of patients reaching the effective phase of treatment (level 1). Compared with the control group, the epidermal growth factor group and the combined group achieved a shorter time for wound repairing to healing stages 2 and 3, and the difference was significant (p < 0.05). The combined group had a shorter wound repairing time than the epidermal growth factor group (p < 0.05). Compared with the control group, the positive rate of bacteria in the combined group and the silver nanoparticles group was significantly lower after 2 and 4 weeks of treatment.Conclusion: There is no significant difference in wound healing between the four groups during the clinically effective period. After this period, the combined use of recombinant epidermis Growth factors and nano-silver dressings have a significant effect on promoting wound healing and can effectively prevent infection.

scholarly journals Epidermal growth factor (EGF) promotes bone healing in surgically induced osteonecrosis of the femoral head (ONFH)

2018 ◽  
Vol 18 (4) ◽  
pp. 352-360 ◽  
Author(s):  
Ozgur Basal ◽  
Tolga Atay ◽  
İbrahim Metin Ciris ◽  
Yakup Barbaros Baykal
Keyword(s):  
Growth Factor ◽  
Femoral Head ◽  
Epidermal Growth Factor ◽  
Bone Healing ◽  
Control Group ◽  
Vascular Density ◽  
Sham Control ◽  
Significant Difference ◽  
Epidermal Growth ◽  
Surgically Induced

Angiogenic effects of epidermal growth factor (EGF), a potent mitogen, have been demonstrated previously. Moreover, different in vitro studies showed that EGF affects processes associated with bone healing, such as osteoblast differentiation and bone resorption. The aim of this study was to investigate the effect of combined core decompression (CD) and recombinant human EGF (rhEGF) treatment on early-stage osteonecrosis of the femoral head (ONFH) surgically induced in rats. ONFH was induced by dissecting the cervical periosteum and placing a ligature tightly around the femoral neck. Thirty rats were assigned to one of the following groups (n = 10 each group): sham-operated control, CD, and CD+rhEGF group. rhEGF was injected intraosseously into infarcted areas 2 weeks after the surgery. Preservation of femoral head architecture was assessed at 8 weeks post treatment by radiographic and histomorphological analyses. Osteopontin (OPN) and cluster of differentiation 31 (CD31) were detected by immunochemistry, as indicators of bone remodeling and vascular density, respectively. Inter- and intra-group (non-operated left and operated right femur) differences in radiographic and histomorphological results were analyzed. The femoral head area and sphericity were more preserved in CD+rhEGF compared to CD and sham-control group. CD31 levels were significantly different between the three groups, and were higher in CD+rhEGF compared to CD group. OPN levels were increased in CD and CD+rhEGF groups compared to sham control, but with no significant difference between CD and CD+rhEGF groups. Overall, our results indicate that EGF promotes bone formation and microvascularization in ONFH and thus positively affects the preservation of femoral head during healing.

A STUDY ON THE ROLE OF EPIDERMAL GROWTH FACTOR IN DIABETIC ULCER MANAGEMENT

2021 ◽  
pp. 62-63
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Diabetic Ulcer ◽  
Epidermal Growth Factor Treatment ◽  
Epidermal Growth ◽  
Diabetic Foot Disease ◽  
Foot Disease

Diabetes mellitus is a disease of large magnitude with 25 million people affected by the disease in India. One of the common complications of this disease is Diabetic foot disease characterised by non-healing ulcers over the foot predominantly. This study is aimed at evaluating the efcacy and tolerability of Recombinant Epidermal Growth Factor treatment in increasing the rate of healing of ulcers and decreasing the duration of ulcer healing among patients with diabetic foot disease thereby improving the quality of life, preventing further morbidity and mortality and shortening hospital stay.

Effectiveness of a synthetic human recombinant epidermal growth factor in diabetic patients wound healing : Pilot , double‐blind , randomized clinical controlled trial

2021 ◽  
Author(s):  
Bianca Campos Oliveira ◽  
Beatriz Guitton Renaud Baptista Oliveira ◽  
Gabriela Deutsch ◽  
Fernanda Soares Pessanha ◽  
Selma Rodrigues Castilho
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Controlled Trial ◽  
Diabetic Patients ◽  
Double Blind ◽  
Epidermal Growth

scholarly journals Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252646
Author(s):  
Margot Geens ◽  
Sofie Stappers ◽  
Heleen Konings ◽  
Benedicte Y. De Winter ◽  
Pol Specenier ◽  
...  
Keyword(s):  
Lymph Node ◽  
Growth Factor ◽  
Lymph Node Metastasis ◽  
Epidermal Growth Factor ◽  
Healthy Volunteers ◽  
Control Group ◽  
Node Metastasis ◽  
Oncological Patients ◽  
Platinum Based Chemotherapy ◽  
Epidermal Growth

In this study, we investigated serum epidermal growth factor (EGF) in an oncological population of head- and neck and pulmonary neoplasms and whether serum EGF could serve as a prognostic marker of survival and as a predictive marker for treatment response to platinum-based chemotherapy. A total of 59 oncological patients and a control group of age- and sex-matched healthy volunteers were included in this study. Pre-treatment serum EGF from both groups was determined. Patient’s and tumour characteristics and mortality were recorded during a 5-year follow up period. Baseline serum EGF significantly differed between the oncological patients and the healthy volunteers (p<0.001). Serum EGF was associated with lymph node metastasis (p = 0.004) but not with sex (p = 0.753), age (p = 1.00), TNM stage (p = 0.191) or tumour size (p = 0.077). Neither serum EGF (p = 0.81) nor age (p = 0.55) showed an effect on the patient’s survival. Tumour location was significantly associated with overall 5-year survival (p = 0.003). The predictive capacity of serum EGF of response to chemotherapy was limited (AUC = 0.606), a sensitivity of 80% and a specificity of 56% was observed resulting in a likelihood ratio of a positive and negative test equal to 1.81 and 0.36, respectively. In conclusion, serum EGF levels are 5.5 times higher in an oncological population compared to a control group. Within the oncological population, low serum EGF values are associated with the presence of lymph node metastasis. Further investigation is necessary to determine if the serum EGF levels could serve as a diagnostic biomarker.

Sign in / Sign up

Export Citation Format

Share Document